IN THE SPOTLIGHT

From Metabolic to Pathologic Complete Response: Case Report of Neoadjuvant Lorlatinib in Stage IIIB ALK-Positive NSCLC Combined with Uniportal VATS

From Metabolic to Pathologic Complete Response: Case Report of Neoadjuvant Lorlatinib in Stage IIIB ALK-Positive NSCLC Combined with Uniportal VATS

Clinical Trial: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Clinical Trial: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

PROtein Analytics for Kinase Therapeutic Inhibitor Variants (PROAKTIV): A Machine learning approach to predict efficacy of tyrosine kinase inhibitors against mutations in EGFR, ALK and BRAF

PROtein Analytics for Kinase Therapeutic Inhibitor Variants (PROAKTIV): A Machine learning approach to predict efficacy of tyrosine kinase inhibitors against mutations in EGFR, ALK and BRAF

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…

Multimodal MRI Deep Learning Noninvasive Prediction of NSCLC Brain Metastases: EGFR/ALK Targeted Driven: Multicenter External Validation Study

Multimodal MRI Deep Learning Noninvasive Prediction of NSCLC Brain Metastases: EGFR/ALK Targeted Driven: Multicenter External Validation Study

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

Utilizing Clinical Pathways in the Treatment of Patients With ALK-Positive NSCLC

Utilizing Clinical Pathways in the Treatment of Patients With ALK-Positive NSCLC

The Future of Lung Cancer Starts Here

The Future of Lung Cancer Starts Here

For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested  $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…

Biggest News from Berlin: Research Highlights from ESMO

Biggest News from Berlin: Research Highlights from ESMO

Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data.  We saw data from studies that aim to build upon…

LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research

LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research

LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…

Celebrating Progress in Lung Cancer: From Detection to Survivorship

Celebrating Progress in Lung Cancer: From Detection to Survivorship

Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…

Veteran Voices: Surgery to Survivorship at the VA

Veteran Voices: Surgery to Survivorship at the VA

Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael.  Michael is a veteran of the Vietnam War and uses the…

6 Tips for Managing Scanxiety

6 Tips for Managing Scanxiety

Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…

Why Do Some People Who Have Never Smoked Get Lung Cancer?

Why Do Some People Who Have Never Smoked Get Lung Cancer?

As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…

Surviving LMD: Michelle Never Settled for “No”

Surviving LMD: Michelle Never Settled for “No”

Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…

Watch HOPE Summit Videos

Watch HOPE Summit Videos

HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…

Integrative Oncology and Lung Cancer: Adding Complementary Therapy

Integrative Oncology and Lung Cancer: Adding Complementary Therapy

What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery, or immunotherapy. Integrative oncology—also called integrative medicine—is an evidence-informed whole-body approach to health. It is often used to address symptoms and side effects caused by disease or treatment and improve overall quality of life. Specific examples of integrative oncology for lung cancer…

What Should Patients Know About Lung Cancer Surgery?

What Should Patients Know About Lung Cancer Surgery?

Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non-small cell lung cancer (NSCLC) staged at I, II, or IIIA. Surgery is rarely considered for tumors at stage IIIB or IV because those lung cancers have spread to other parts of the body. It is also rarely used to treat small cell lung cancer (SCLC) because SCLC is typically diagnosed at a later stage.  Types of…

Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation

Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…

How Do We Treat Early-Stage NSCLC in 2025?

How Do We Treat Early-Stage NSCLC in 2025?

Roughly 20% of lung cancer is diagnosed as early-stage disease, and researchers have been working to improve treatment options for these patients—with significant success.  Last September, as part of LUNGevity’s International Lung Cancer Survivorship Conference, we hosted a session on the progress in treating early-stage non-small cell lung cancer (NSCLC) with Dr. Jarushka Naidoo of Beaumont RCSI Cancer Centre in Ireland and Dr. Amy Moore of LUNGevity Foundation. In October,…

Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer

Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer

Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…

Staying Safe From Smoke, Pollution, and Dangerous Air Quality

Staying Safe From Smoke, Pollution, and Dangerous Air Quality

On the West Coast, wildfires are taking human lives and destroying homes. On the East Coast, the devastating results of Hurricane Helene are leading to illegal open burning of debris and trash. Thousands of miles separate these fires, but the results are the same—dangerous particles are entering the air we breathe. LUNGevity spoke with Angela Hopper, an 11-year lung cancer survivor who spent 30 years working as an air quality specialist at the North Carolina Department of Environmental…

Have You Heard About Cancer Cachexia?

Have You Heard About Cancer Cachexia?

Cachexia is a complex condition that causes severe muscle and weight loss, physical inactivity, and metabolic disruptions such as fatigue, nausea, and loss of concentration. It's estimated that 50% of individuals with lung cancer experience cachexia at some point.Learn more about cachexia and how to recognize the symptoms. 

Conversations that Count: Understanding the Complexities of Race and Health

Conversations that Count: Understanding the Complexities of Race and Health

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In January, we welcomed Matthew McCurdy, MPH, co-founder and executive director of BLKHLTH, to speak on the complexities of race and…

Real-World Examples of Patient Involvement in Designing Clinical Trials

Real-World Examples of Patient Involvement in Designing Clinical Trials

Read time: 2 minutes.Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials.  In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can…

Developing Clinical Trials that Account for the Realities of Patient Life

Developing Clinical Trials that Account for the Realities of Patient Life

Read time: 2 minutes.  We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials.  In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about.  If you missed the first video, How Can Patients…

Our Dream Was to Start a Family, but Lung Cancer Changed Everything

Our Dream Was to Start a Family, but Lung Cancer Changed Everything

Read time: 6 minutes. After a few unimpressive encounters I experienced in real life, I tentatively returned to the Match dating app. That’s where I stumbled upon a very sweet, kind-hearted, nerdy, and compassionate man. Then I met Nate (Ha! Just joking). It was Nate. We bonded so quickly during which we identified our life goals. One goal was to have a family.  Yes, we did the whole “let’s get ready” experience. We invested in a new SUV. We were eyeing new housing…